Emergent BioSolutions Inc...

NYSE: EBS · Real-Time Price · USD
9.02
0.18 (2.04%)
At close: Aug 18, 2025, 3:34 PM

Emergent BioSolutions Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-190.6M -760.5M -223.8M 230.9M
Depreciation & Amortization
108.8M 125.1M 143.3M 123.8M
Stock-Based Compensation
18M 23.1M 45.1M 42.4M
Other Working Capital
170.6M -59.9M -48.3M -61.7M
Other Non-Cash Items
39.3M 485.2M 19.8M 33.5M
Deferred Income Tax
-5.5M -8.9M -19M 46.9M
Change in Working Capital
88.7M -70.3M 500K -156.4M
Operating Cash Flow
58.7M -206.3M -34.1M 321.1M
Capital Expenditures
-22.9M -51.6M -115.8M -225M
Cash Acquisitions
n/a 270.2M n/a n/a
Purchase of Investments
n/a n/a n/a n/a
Sales Maturities Of Investments
n/a n/a n/a n/a
Other Investing Acitivies
148.1M -6.3M -265.5M n/a
Investing Cash Flow
125.2M 212.3M -381.3M -225M
Debt Repayment
-198.4M -543.4M 564.2M -35.9M
Common Stock Repurchased
n/a n/a -82.1M -106M
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
-1.2M -700K -900K 900K
Financial Cash Flow
-190M -535.7M 481.2M -141M
Net Cash Flow
-6.1M -530.9M 66.3M -45.2M
Free Cash Flow
35.8M -257.9M -149.9M 96.1M